Life Sciences Law & Industry Report connects the dots among the many disciplines that make up the burgeoning life sciences industry, with biweekly updates on current regulatory, legislative,...
July 13 — If Congress doesn't pass a budget by the end of the year, it would set back medical research, two Senate appropriators said July 13.
“Continuing resolutions take all the money away,” Sen. Lindsey Graham (R-S.C.) said, adding that there may a short-term resolution when the fiscal year ends Sept. 30 due to this “crazy thing called an election.” “But I am not going to vote for a continuing resolution that goes into the next Congress. We need to solidify and maintain the gains we’ve achieved this budget year.”
The National Institutes of Health is poised to see some type of increase in FY 2017 to its $32 billion budget, as the Senate has proposed a $2 billion increase, the House has offered a $1.25 billion increase, and President Barack Obama's budget would provide an $825 million increase (10 LSLR 15, 7/22/16). The increases aim to reverse more than a dozen years of flat funding that have resulted in a 20 percent decline in the NIH's purchasing power.
“When it comes to NIH and funding, the best days are yet to come,” Graham said.
Sen. Richard J. Durbin (D-Ill.) agreed that a continuing resolution is “not going to give us that growth” to fund programs like the Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative.
“If we screw this up with a continuing resolution, it’s going to unfortunately not give us that growth for however long that runs. Secondly, if we get into some kind of budget deal that brings down the numbers in the Senate for spending in this area, we may lose in this exchange,” Durbin said. “This is something we can and must do,”
Graham and Durbin are co-chairmen of the Senate NIH Caucus and delivered opening remarks at a July 13 briefing, “NIH Funding and the Promise Of NIH Alzheimer’s Research.” The research funding advocacy group ActforNIH organized the briefing on the same day that the White House held a conference on aging that included several initiatives for living with Alzheimer's disease and related diseases. One of the speakers at the briefing, Ronald C. Petersen, director of the Mayo Clinic's Alzheimer’s Disease Research Center, Rochester, Minn., also testified during a Senate Finance Committee hearing on Alzheimer's disease later that day.
Laurie Ryan, chief of the Dementias of Aging branch in the National Institute on Aging, part of the NIH, said the $2 billion increase in 2016 provided her institute with a 4.2 percent increase. She said that money will help the agency meet its goals under a national plan released four years ago to prevent or effectively treat Alzheimer’s by 2025.
“There’s a lot of research that we haven't been able to fund,” Ryan said. “We’re very confident that the field is ready.”
David A. Bennett, who director the Alzheimer's disease center at Rush University Medical Center in Chicago, said, “The roadmap for what needs to be done is generally clear. So what the additional money will do is it will allow us to do that work in parallel rather in series.”
Ryan said the NIA will release this summer a 2018 bypass budget on Alzheimer's disease, or the agency's estimate of additional funding needed to meet the goal of finding effective treatments and preventions for Alzheimer’s disease and related dementias by 2025. The first-ever NIH bypass budget on Alzheimer's went out last August (10 LSLR 15, 7/22/16).
To contact the reporter on this story: Jeannie Baumann in Washington email@example.com
To contact the editor responsible for this story: Randy Kubetin firstname.lastname@example.org
Copyright © 2016 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)